What Happens If You Fall Pregnant on Wegovy

Step one: stop Wegovy and contact your GP or midwife today

The moment pregnancy is confirmed (or if you suspect you might be pregnant) the right first step is to stop your Wegovy injections and get in touch with a healthcare professional the same day. This is not a situation that benefits from waiting for a scheduled repeat prescription review. Your GP, a midwife, or an urgent care line can all advise you directly.

Semaglutide clears from the body gradually over several weeks because of its long half-life, so even after the last injection there will be residual levels in your system for a period. That is another reason early contact with a clinician matters: they can factor the timing of your last dose into their assessment and refer you to antenatal services promptly. It is also worth being aware of how long before Wegovy expires if you have unused pens at home, so you are not left uncertain about whether to dispose of or store them while you await clinical guidance.

You do not need to taper the dose before stopping. Abrupt discontinuation is appropriate here, and what to expect physically when Wegovy is stopped is different in a pregnancy context from elective pausing, your clinical team will guide you through both the obstetric and the metabolic side of things.

Step two: understand what the current evidence actually says

There is no large dataset of human pregnancies where Wegovy was taken throughout, which means certainty is limited in both directions. The Wegovy Summary of Product Characteristics, referenced on the eMC, advises against use in pregnancy based on animal reproductive toxicity studies that showed foetal growth effects at doses exceeding clinical exposure levels. The SmPC and prescribing guidance class it as not recommended, and that position has not changed with the higher 7.2mg dose approval.

What is not known: whether brief early-pregnancy exposure at lower doses carries measurable risk in humans. The data simply do not exist yet. That uncertainty is not reassurance, it is the reason the guidance defaults to stopping promptly rather than continuing until more information is available.

NHS guidance on weight-management injections is consistent on this point: these medicines are not suitable during pregnancy, and the recommendation to stop applies across the GLP-1 class. If you want a fuller picture of how Wegovy works in the body, that context can help you understand why pregnancy changes the clinical calculus entirely.

Step three: plan contraception after any future treatment

If your pregnancy was unplanned and you are considering returning to weight-management treatment after giving birth or after any other outcome, the conversation about contraception belongs at the start of that discussion, not as an afterthought.

The MHRA advises using effective contraception while taking GLP-1 medicines and for a defined wash-out period before trying to conceive. For semaglutide, that wash-out guidance is set out by your prescriber based on the drug's pharmacokinetics, roughly two months is commonly referenced, though your clinical team will confirm the current figure for your circumstances.

One practical point worth knowing: Wegovy does not directly reduce the effectiveness of the combined oral contraceptive pill the way tirzepatide is known to in the early weeks of treatment. NHS England's guidance notes no equivalent evidence of reduced pill absorption for semaglutide. That said, vomiting (one of the more common early side effects) can affect any oral medication taken on the same day, so your prescriber may still discuss back-up contraception for periods of significant nausea. You can read more about when side effects typically begin after starting Wegovy to understand the timeline.

For a broader overview of the treatment, including how it is accessed privately through a regulated pharmacy, the Wegovy treatment page covers the full picture. If after everything settles you want to explore your options, checking your eligibility with our prescribers is the natural starting point.

What breastfeeding and trying to conceive mean for future treatment

Wegovy is not recommended during breastfeeding either. Semaglutide has been detected in the milk of lactating animals, and while the clinical significance for human infants is not established, the precautionary position is consistent: avoid it until breastfeeding has ended and the wash-out period has passed.

For people actively trying to conceive, the same guidance applies, effective contraception while on treatment, and stopping before attempting pregnancy. This is true of the injection and, as of summer 2026, of the newly approved oral form as well. The MHRA's Yellow Card scheme exists partly to capture real-world pregnancy outcomes for medicines like this, and reporting any exposure (even inadvertent) helps build the evidence base over time.

If you stopped Wegovy some time ago and are curious about what happens to weight after treatment ends, that is a separate but related question many people have when planning ahead. Our prescribers can talk through timing and planning as part of a future consultation.